Paul Sorajja

Paul Sorajja, MD

Roger L. and Lynn C. Headrick Family Chair and Director, MHIF Valve Science Center

Dr. Paul Sorajja is the Roger L. and Lynn C. Headrick Family Chair of the Valve Science Center at the Minneapolis Heart Institute Foundation, and a cardiologist at Minneapolis Heart Institute® where he serves as the Director of the Center for Valve and Structural Heart Disease. He received his medical degree from Mayo Medical School, and completed his Internal Medicine Residency and Cardiology Fellowship at the Mayo Graduate School of Medicine. During 1998-99, he was a clinical research fellow in myopathy at St. George’s Hospital in London, UK. Dr. Sorajja joined the Mayo Clinic staff in 2006, achieving the rank of Professor of Medicine in 2012. In 2013, Dr. Sorajja joined the Minneapolis Heart Institute® at Abbott Northwestern Hospital.

Dr. Sorajja’s expertise is interventional cardiology, with a focus on bringing the latest innovative technologies to patients with valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement (TMVR) in the US, and has the largest worldwide experience with the therapy. Dr. Sorajja currently serves as a national investigator for TMVR and also for clinical trials in percutaneous treatment for tricuspid regurgitation. He has served on several national practice committees for valvular heart disease and hypertrophic cardiomyopathy. Dr. Sorajja has published more than 250 manuscripts and several books. He routinely lectures at national and international medical conferences, and has received awards for his expertise in medical education. Dr. Sorajja is also highly active in developing intellectual property in these areas.

Back to Heart Attack Team Back to Valve Team

Image
Twitter Icon
Image
LinkedIn Icon
Paul Sorajja

Professional Interests:

  • Heart valve disease (e.g., mitral regurgitation, aortic stenosis, tricuspid regurgitation)
  • Structural heart disease and interventions
  • Hypertrophic cardiomyopathy
  • Coronary atherosclerosis
  • Percutaneous coronary intervention
Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.